Clinical Trial Update: Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial update of homoharringtonine (Omacetaxine mepesuccinate) in chronic myeloid leukemia with the T315I BCR-ABL mutation; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Homoharringtonine (omacetaxine mepesuccinate) (omacetaxine mepesuccinate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2014-06-03